Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    Intensive Lipid Lowering Reduces Cardiovascular Events in High-Risk Patients: Reported at ACC - (DGDispatch)
    Decrease in EEG Slow-Wave Activity Can Predict Response to Rivastigmine in AD: Presented at ADI - (DGDispatch)
    Valsartan Slows Diabetes Progression, but Does Not Prevent Cardiovascular Events: Presented at ACC - (DGDispatch)
    Rivastigmine Shows Promise for Patients With Parkinson's Disease Dementia: Presented at ADI - (DGDispatch)
    Intensive BP Lowering Fails to Show Cardiovascular Benefit in High-Risk Patients With Diabetes: Presented at ACC - (DGDispatch)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
    • Translating Guidelines Into Practice: An Expert Roundtable Discussion of Optimal Antiplatelet Therapy in Acute Coronary Syndrome
    • Confronting the Growing Challenge of Preserving Renal Function Following Liver Transplantation
      Type 2 Diabetes in Adolescents
      Tools for Supporting Optimal Fibromyalgia Diagnosis and Treatment: An Update for Primary Care and Managed Care
      Deep Vein Thrombosis in Focus: Expert Perspectives on Reducing the Burden of Venous Thromboembolism

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Daptomycin For Methicillin-Resistant Staphylococcus Epidermidis Native-Valve Endocarditis: A Case Report
        Daptomycin For Treatment Of Methicillin-Resistant Staphylococcus Epidermidis Saphenectomy Wound Infection After Coronary Artery Bypass Graft Operation (CABG): A Case Report
        Transient Bilateral Abducens Neuropathy With Post-Tetanic Facilitation And Acute Hypokalemia Associated With Oxaliplatin: A Case Report
        Cardiac Surgery In A Patient With Retroperitoneal Fibrosis And Heart Valvulopathy, Both Due To Pergolide Medication For Parkinson's Disease
        Methemoglobinemia Presenting In A Circumcised Baby Following Application Of Prilocaine: A Case Report

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Home Recorded Sleep With Fluvoxamine Similar To That Seen In Laboratory With Other Antidepressants

        A DGReview of :"Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers"
        Journal of Psychopharmacology

        01/26/2001
        By Veronica Rose


        Home recorded sleep findings following fluvoxamine were similar to sleep laboratory studies using other antidepressant drugs.

        Researchers designed a placebo-controlled, double-blind, cross-over study to establish the effects on night-time sleep, drowsiness and performance the following day.

        Participants included 12 normal volunteers who were given a single dose of fluvoxamine 100 mg, dothiepin 100 mg or placebo.

        Both drugs altered night-time sleep significantly with main effects on rapid eye movement (REM) sleep and sleep continuity.

        There was increased total sleep time, latency in rapid eye movement, sleep, stage 2 sleep and decreased arousal with dothiepin, which also affected wake after sleep onset and stage 1 sleep.

        Fluvoxamine, however, decreased total sleep and rapid eye movement times and increased wake after sleep onset.

        Dothiepin shortened sleep latency in daytime naps, but proved longer with fluvoxamine. This, researchers suggested, was an indication that subjects were sleepier after taking dothiepin. However, electroencephalogram (EEG) performed during performance tasks failed top make any significant distinction between drugs.

        Researchers also found no significant variations between the groups on their tracking performance measures or reaction time. It was noted that these tasks were designed primarily to provide them with a standard setting for monitoring continuous EEG. Consequently, they were unsuitable for detecting sleepiness effects themselves.

        Saccadic eye movement velocity, acceleration and deceleration indicated small, non-significant changes following administration of both drugs. There was no significant difference among the groups in mood self-ratings.

        Subjective measures of night-time sleep reflected the objective measures of sleep continuity. The items for difficulty and speed awakening in the morning were significantly slower and more difficult, therefore, higher in the dothiepin group.
        Journal of Psychopharmacology.Vol 14 Issue 4. "Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send